火狐体育官网平台

News & Trends

• 142025-02

  SAL0140 Clinical Trial Application Accepted by NMPA, Potential Breakthrough in Hypertension Treatment

• 202025-01

  Announcement of the Positive Interim Data from the Phase 2 Trial of JK07 in Heart Failure

• 282024-11

  Salubris’innovative drugs Xinliting and FoLitan ® have been included in China's national reimbursement drug list

• 272024-08

  Salubris obtaining the exclusive right of base editing drug YOLT-101

• 052024-08

  The innovative anti-tumor drug JK06 was approved for overseas clinical trial

• 012024-08

  Enarodustat’s new indication approved for clinical trial